Инфаркт миокарда без элевации ST и риск-стратификация повторных кардиоваскулярных событий в постинфарктном периоде у больных с метаболическим синдромом
Диссертация
Течение и исходы инфаркта миокарда у больных с метаболическим синдромом изучены недостаточно. В работах G. Levantesi (2005) показано, что инфаркт миокарда у больных с метаболическим синдромом характеризуется большей частотой внутригоспитальных осложнений. В то же время, предикторы осложнений не изучены, а риск внутригоспитальных осложнений остается не разработанным. M. Zeller с соавторами в 2005… Читать ещё >
Список литературы
- Алмазов В.А., Благосклонная Я. В., Шляхто Е. В., Красильникова Е. В. Метаболический сердечно-сосудистый синдром. СПб: Издательство СПбГМУ, 1999.-202 с.
- Аметов A.C., Орлов В. А., Жестовский С. С. Особенности безболевой ишемии миокарда у больных инсулиннезависимым сахарным диабетом. Опыт применения персантина//Проблемы эндокринологии. 1997. — Т.4. — С. 9−13.
- Беляков H.A., Чубриева С. Ю., Великанова Л. И. Ишемические изменения миокарда при метаболическом синдроме по данным Холтеровского мониторирования электрокардиограммы//Вестник аритмологии. 2000. -Т.16. — С.28−31.
- Богова О.Т., Чукаева И. И. Инфаркт миокарда. Воспаление и прогноз//Российский кардиологический журнал. 2003. — Т. 4. — С.95−98.
- Бокерия Л. А., Голухова Е. З., Ивапицкий A.B. Функциональная диагностика в кардиологии в 2-х томах. Москва: НЦССХ им. А. Н. Бакулева РАМН, 2005.-Т.1. — С.35.
- Дороднева Е.А., Пугачёва Т. А., Медведева И. В. Метаболический синдром// Терапевтический архив. 2002. — Т. 10. — С.7−12.
- Дупляков Д.В. Антитромбоцитарная терапия у больных сахарным диабетом//Кардиоваскулярная терапия и профилактика. 2004. — Т.5. — С. 126−33.
- Кабалава Ж.Д. Современные проблемы артериальной гипертонии. -Москва: Solvay Pharma, 2003. С.6−23.
- Казакова И.А. Анализ состояния эритроцитарных мембран у больных хронической почечной недостаточностью при синдроме инсулинорезистентности//Проблемы экспертизы в медицине. 2004. — Т.4, № 3. — С.28−31.
- Мамедов М.Н., Оганов Р. Г. Эпидемиологические аспекты метаболического синдрома//Кардиология. 2004. — Т.44, № 9. — С.4−9.
- Никитин Н.П., Аляви A.JI. Особенности диастоличсской дисфункции в процессе ремоделирования левого желудочка сердца при развитии хронической сердечной недостаточности//Кардиология. 1998. — Т. З, № 1. -С.56−61.
- Первые Российские рекомендации ВНОК по диагностике и лечению метаболического синдрома (второй пересмотр). Москва: Комитет экспертов Всероссийского научного общества кардиологов, 2008.
- Ройтберг Г. Е., Тихоправов A.B., Ушакова Т. И., Дорош Ж. В. Взаимосвязь полиморфизма гена АПФ с развитием инсулинорезистентности и компенсаторной гиперинсулинемии/ЛДитология и генетика. 2005. — Т.1. — С. 63−70.
- Синицын П.А., Щербакова М. Ю., Ларионова В. И., Петряйкина Е. Е. Метаболический синдром у детей//Педиатрия Журнал им. Г. Н. Сперанского. 2008. — Т.87, № 5. — 124−127.
- Шамсеев М.Р., Бондарева З. Г., Аронов Е. А., Цыба Л. П., Беленький Д. И., Федорова Д. Л. Острый коронарный синдром: диагностическая и прогностическая ценность тропонина I и кардиоспецифических ферментов/УБюллетень СО РАМН. 2003. — Т. 109, № 3. — С.42−46.
- Шляхто Е.В., Конради А. О. Эпидемиология метаболического синдрома в различных регионах. Зависимость от используемых критериев ипрогностическое значение//Артериальная гипертензия. 2007. — Т. 13, № 2. -С. 95−111-
- Agema W., Montraats P., Sawinderman A., et al. Current PTCA practice and clinical outcomes in the Netherlands: the real world in the predrug-eluting stent era//Eur Heart J. 2004. — V.25. — P. l 163−70.
- Ahmed A., Shankar K.J., Eftekhari H., et al. Silent myocardial ischemia: Current perspectives and future directions//Exp Clin Cardiol. 2007. — V.12,№ 4. -P.189−196.
- Allen L.A., O’Donnell S.G., Camargo C.A., et al. Comparison of long-term mortality across the spectrum of acute coronary syndromes//Am Heart J. 2006. -V.151. — P.1065−1071.
- Apeterei E., et al. C-reactive protein, prothrombotic imbalance and endothelial dysfunction in acute coronary syndromes without ST elevation//Rom J Int Med. -2004. — V.42. — P.95−102.
- Ardissino D., Merlini P., Ariens R., Coppola R., Bramucci E., Mannucci P. Tissue-factor antigen and activity in human coronary atherosclerotic plaques// Lancet. 1997.- V.349. — P.769−771.
- Berton G., Cordiano R., Palmieri R, Pianca S., Pagliara V., Palatini P. C-reactive protein in acute myocardial infarction: association with heart failure//Am Heart J. 2003. — V. 145, № 6. — P. 1094−101.
- Blankenberg S, Rupprecht H, Bichel C, et al. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease//N Engl J Med. -2003.-V.349.-P.1605−1613.
- Body V., Sanchis J., Nunes J., Mainar L., Minana G., et al. Uncontrolled immune response in acute myocardial infarction: Unraveling the thread//Am Heart J. 2008. — V. 156. — P. 1065−73.
- Bonow R.O., Udelson J.E. Left ventricular dysfunction as cause of congestive heart failure//Ann Intern Medicine. 1992. -V.l 17, № 6. — P. 502−10.
- Brook R, Bard R, Rubenfire M, et al. Usefulness of visceral obesity (waist/hip ratio) in predicting vascular endothelial function in healthy overweigh adults//Am J Card. 2001. — V.88. — V. 1264−1269.
- Burchfiel C., Sharp D., Curb J., Rodriguez В., Abbott R., et al. Hyperinsulinemia and cardiovascular disease in elderly men: the Honolulu Heart Program//Arterioscler Thromb Vase Biol. 1998. — V.18. — P.450−457.
- Capes S.E., Hunt D., Malmberg K., Gerstein H.S. Stress hyperglycemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview//Lancet. 2000. — V.355. — P.773−778.
- Carr D., Utzschneider K., Hull R., et al. Intra-abdominal fat is a major determinant of the National Cholesterol Education Program Adult Treatment Panel III criteria for the metabolic syndrome//Diabetes. 2004. — V.53,№ 8. — P.2087−94.
- Cesari M, Penninx B, Newman A, et al. Inflammatory markers and cardiovascular disease (the Health, Aging and Body Composition (Health ABC) Study)//Am J Cardiol. 2003.- V.92. — P.522−528.
- Cesari M, Penninx B, Newman A, et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study//Circulation. 2003. -V.l08. — P.2317−2322.
- Cultip D., Chauhan M., Baim D., et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials//J Am Coll Cardiol. 2002.- V.40. P.2082−89.
- Davies M.J., Thomas A.C., Knapman P.A., Hangartner J.R. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death//Circulation. 1986. — V.73. — P.418−427.
- Davies M.J. The pathophysiology of acute coronary syndromes//Heart. 2000.- Y.83. P.361−366.
- Deedwania PC. Diabetes as a vascular disease: the role of endothelial dysfunction in pathophysiology of cardiovascular disease in diabetes//Cardiol Clin.- 2004. V.22. — P.505−509.
- Deedwania PC. Metabolic syndrome and vascular disease. Is nature or nurture leading the new epidemic of cardiovascular disease?//Circulation. 2004. — V.109. -P.2−4.
- Dekker M, Girman C., Rhodes T., et al. Metabolic Syndrome and 10-Year Cardiovasculas Disease Risk in the Hoorn Study//Circulation. 2005. — V. l 12. -P.666−673.
- Doughty R.N., Rodgers A., et al. Effect of beta-blocker therapy on mortality in patients with heart failure//Eur Heart J. 1997. — V. 18. — P.560−65.
- Empana J.-P., Duciemetiere P., et al. Contribution of the metabolic syndrome to sudden death risk in asymptomatic men: the Paris Prospective Study I//Eur Heart J. 2007. — V.28. — P. l 149−1154.
- Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes//Endocr. Rev. 2002. — V.23. — P.599−622.
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)//JAMA. 2001. — V. 285. — P. 2486−2497.
- Festa A, D’Agostino R, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS)//Circulation. 2000. — V.102. — P.42−47.
- Festa A, Hanley A, Tracy R, et al. Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion// Circulation. 2003. — V. 108. — P. 1822−1830.
- Fichtlscherer S., Breuer S, Zeiher A. Prognostic value of systemic endothelial dysfunction in patients with acute coronary syndromes//Circulation. 2004. -V.l 10. — P.1926−1932.
- Fitzgerald D., Roy L., Catella F., Fitzherald G. Platelet activation in unstable coronary disease//N Eng J Med. 1986. — V.315. — P.983−989.
- Ford E. Risks for All-Cause Mortality, Cardiovascular Disease, and Diabetes Associated with the Metabolic Syndrome//Diabetes Care. 2005. — V.28, № 7. — P. 1769−1778.
- Ford E.S., Giles WH, Dietz WH. Prevalence of metabolic syndrome among U.S. adults: Findings from the Third National Health and Nutrition Examination Survey//JAMA. 2002. — V.287. — P.356−359.
- Fuentes L, Brown AL, Mathews SJ, Waggoner AD, Soto PF, Gropler RJ, Davila-Roman VG. Metabolic Syndrome is Associated with Abnormal Left Ventricular Diastolic Function Independent of LV Mass//Eur Heart J. 2007. -V.28, № 5. — P. 553−559.
- Galderisi M. Diastolic dysfunction and diastolic heart failure: diagnostic, prognostic and therapeutic aspects/VCardiovascular Ultrasound. 2005. — V.3, № 9. -P. 1−14.
- Galderisi M., Paolisso G., Tagliamonte MR, Alfieri A., et al. Is insulin action a determinant of left ventricular relaxation in uncomplicated essencial hypertension?//Journal of Hypertension. 1997. — V.15, №.7. — P. 745−50.
- Gami A., Howard D., Somers V., Montori V. Metabolic Syndrome and Risk of Incident Cardiovascular Events and Death// J Am Coll Cardiol. 2007. — V.49, № 4.-P. 403−414.
- Gibson C, Pinto D, Murphy S., Morrow D. et al. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol. 2003. — V.42. — P. 1535−1543.
- Ginsburg G., et al. Prospects for Personalized Cardiovascular Medicine: The Impact of Genomics//JACC. -2005. V.46, № 9. -P. 1615−1627.
- Giugliano R.P., Braunwald E. The Year in Non-ST-Segment Elevation Acute Coronary SyndromeV/J Am Coll Cardiol. 2007. -V.50. — P. 1386−1395.
- Goncalves P., Ferreira J., Aguiar C., R. Seabro-Gomes. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS//Eur Heart J. 2005. — V.26. — P.865−872.
- Gonzalez-Sanchez J. et al. Endothelial Nitric Oxide Synthase Haplotypes Are Associated With Features of Metabolic Syndrome//Clinical Chemistry. 2007. -V.53,№ 1. — P.91−97.
- Gopaul NK, Manraj M, Heb A, et al. Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritans with impaired glucose metabolism//Diabetologia. -2001. V.44. — P.706−712.
- Greenfield J, Samaras K, Jenkins A, et al. Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences//Circulation. 2004. — V.109. — P.3022−3028.
- Grundy S., Cleeman J., Daniels S., et al. Diagnosis and Management of the Metabolic Syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement: Executive Summary//Circulation. 2005. -V.l 12.-P.285−90.
- Hackel DB, Reimer KA, Ideker RE, Mikat EM, Hartwell TD, Parker CV, Braunwald EB, Buja M, Gold HK, Jaffe AS. Comparison of enzymatic and anatomic estimates of myocardial infarct size in man//Circulation. 1984. — V.70. — P.824−835.
- Hale A, Pols FI, Stehouwer C, et al. Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam Study//J Clin Endocrinol Metab. 2001. — V.86. — P.4398−4405.
- Hansson J., Libby P., Schonbeck U., Yan Z. Innate and adaptive immunity in the pathogenesis of atherosclerosis//Cir Res. 2002. — V.91. — P.281 -291.
- Hartmann F., Kampmann M., Frey N., Muller-Bardorff M., Katus H.A. Biochemical markers in the diagnosis of coronary artery disease//Eur Heart J. -1998.-V.19-P. 2−7.
- Hiroaki Y., Harumizu S., Tamotsu T., et al. Increased Incidences of Coronary Vasospasm by Acetylcholine Injection in Patients with Metabolic Syndrome//Circ J. -2007. V.71, Supplement l.-P. 327.
- Hudson M.P., Christenson R.H., Newby L.K. Cardiac markers: point of care testing//Clin. Chim. Acta. 1999. — V.284, № 2. — P.223−37.
- Hu Gang, Giao Ging, Tuomilehto Jaakko et al. Prevalence of the Metabolic Syndrome and Its Relation to All-Cause and Cardiovascular Mortality in Nondiabetic European Men and Women//Arch Intern Med. 2004. — V. 164. — P. 1066−1076.
- Irshad M, Chaudhuri P. Oxidant-antioxidant system: role and significance in human body//Indian J Exp Biol. 2002. — V.40. — P. 1233−1239.
- Isomaa B., Almgren P., Tuomi T. et al. Cardivascular morbidity and mortality associated with the metabolic syndrome//Diabetes Care. 2001. — V.24. — P.683−689.
- Jaffe A., Ravkilde J., Roberts R. et al. It’s time to change to a troponin standard//Circulation. 2000. -V. 12. — P. 1216—1220.
- Jeppesen Jorgen, Hansen T., Rasmussen S., et al. Insulin Resistance, the Metabolic Syndrome, and Risk of Incident Cardiovascular Disease/VJ Am Coll Cardiol. 2007. — V.49. — P.2112−2119.
- Katsuki A., et al. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes//Diabetes Care. 2000.-V.24, № 2,-P.362−5.
- Kloner RA, Shook T, Przyklenk K, et al. Previous angina altersin-hospital outcome in TIMI 4: a clinical correlate to preconditioning?//Circulation. 1995. -V. 91. -P.37−47.
- Kojima S., Sakamoto T., Ishihara M., Kimura K., et al. Prognostic usefulness of serum uric acid after acute myocardial infarction (the Japanese Acute Coronary Syndrome Study)//Am J Cardiol. 2005. — V. 96, № 4. — P.489−95.
- Lakka H-M, Laaksonen DE, Lakka T-A et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men//JAMA. 2002. -V.288. — P.2709−16.
- Langenberg C., Bergstrom J., Scheidt-Nave C., Pfeilschifter J., Barrett-Connor E. Cardiovascular death and the Metabolic Syndrome//Diabetes Care. 2006. -V.29, № 6.-P. 1363−1369.
- Levine B.T., Levine A.B. Metabolic syndrome and cardiovascular disease. -Sydney: Sounders Elsevier, 2006. 488 p.
- Levantesi G., Macchia A., Marfisi R.-M., et al. Metabolic Syndrome and Risk of Cardiovascular Events After Myocardial Infarction// Journal of the American College of Cardiology. 2005. — V.46, № 2. — P. 277−83.
- Libby P. Current concepts of the pathogenesis of the acute coronary syndromes//Circulation. 2001. -V. 104. — P. 364−372.
- Libby P. Vascular biology of atherosclerosis: overview and state of the art//Am J Cardiol.-2003.-V.92, Suppl.l. P.3A-6A.
- Lindahl B., Diderholm E., Lagerqvist B., Venge P., Wallentin L. Mechanisms behind the prognostic value of Troponin T in unstable coronary artery disease: a FRISC II substudy//J Am Coll Cardiol. 2001. — V. 38. — P.979−986.
- Lindahl B., Toss H., Sliegbanh A., et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease//N Engl J Med. 2000. — V.343. — P. 1139−1147.
- Lopes C., Dina C., Durand E., Froguel P. PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population//Diabetologia. 2003. — V.46, № 9. — P. 1284−90.
- Madala M., Franklin B., Chen A., et al. Obesity and Age of first Non ST-Segment Elevation Myocardial Infarction//J Am Coll Cardiol. 2008. — V.52. — P. 979−985.
- Marette A. Mediators of cytokine-induced insulin resistance in obesity and other inflammatory settings//Curr Opin Clin Nutr Metab Care. 2000. — V.5. -P.377−383.
- Mather KJ, Hunt AE, Steinberg HO, et al. Repeatability characteristics of simple indices of insuline resistance: implications for research complications//! Clin Endocrinol Metab. 2001. — V.86. — P.5457−5464.
- Mazzone A, De Servi S, Ricevuti G, et al. Increased expression of neutrophil and myocyte adhesion molecules in unstable coronary artery disease//Circulation.-1993. V.88. -P.358−363.
- Mils R, Bhatt D, et al. The yin and yang of arterial inflammation//J Am Coll Cardiol. 2004. — V.44. — P.50−52.
- Mizuno K, Satomura K, Miyamoto A, Arakawa K, Shibuya T, Arai T, Kurita A, Nakamura H, Ambrosi JA. Angioscopic evaluation of coronary-artery-thrombi in acute coronary syndromes//N Engl J Med. 1992. — V.326. — P.287−291.
- Monassier D. Non ST elevation acute coronary syndromes and normal coronary angiography: is it truly good news?//Ann Cardiol Anqeiol. 2008. -V.57,№ 5. — P.275−83.
- Monti L.D., Barlassina C., Citterio L., et al. Endothelial nitric oxide synthase polymorphisms are associated with type 2 diabetes and the insulin resistance syndrome//Diabetes. 2003. — V.52, № 5. — P. 1270−5.
- Munzel T, Feil R, Mulsch A, et al. Physiology and pathophysiology of vascular signaling controlled by cyclic guanosine 3'-5'-cyalic monophosphate-dependent protein-ldnase//Circulation. 2003. — V. 108. — P.2172−2183.
- Nadkar M, Jain V. Serum Uric Acid in Acute Myocardial Infarction//Journal of Association of Physicians of India. 2008. — V.56. — 759−62.
- Ninomiya JK, L’ltalien G, Criqui MH, et al. Assosiation of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutricion Examination Survey//Circulation. 2004. — V.109. — P.42−46.
- Nunes J, Nunes E, Sanochis J., et al. Prognostic value of leukocytosis in acute coronary syndromes: the Cinderella of inflammatory markers//Curr Med Chem. -2006.-V.13.-P.2113−8.
- Ottani F, Galvani M, Ferrini D, et al. Prodromal angina limits infarct size: a role for ischemic preconditioning//Circulation. 1995. — V. 91. — P. 291−7.
- Pai J, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women//N Eng J Med. 2004. — V.351. — P.2599−2610.
- Park K" You K., Oh S., Chae I-H, Kim H-S, Oh B-H, Lee M-M, Park Y-B. Association of endothelial constitutive nitric oxide polymorphism with acute coronary syndromes in Koreans//Heart. 2004. — V.90. — P.282−25.
- Pasupathi P., Yagneswara R., Farook J, et al. Oxidative Stress and Cardiac Biomarkers in Patients with Acute Myocardial Infarction//European Journal of Scientific Research. 2009. — V.2. — P.275−285.
- Patel M.R. et al. Prognostic Usefulness of White Blood Cell Count and Temperature in Acute Myocardial Infarction (from the CARDINAL Trial)//J Am Coll Cardiol. 2005. — № 95. — P.614−618.
- Pepys M, Hirschfield G. C-reactive protein: a critical update//J Clin Invest. -2003. V. 111. — P. 1805−1812.
- Pickup J, Crook M. Is type II diabetes mellitus a disease of the innate immune system?//Diabetologia. 1998. — V.41. — P. 1241−1248.
- Pradhan A, Manson J, Rossouw J, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women’s Health Initiative Observational study//JAMA. 2002. — V. 288. — P.980−987.
- Rana J., Monraats P., Aeillco H. Zwinderman, et al. Metabolic Syndrome and Risk of Restenosis in Patients Undergoing Percutaneous Coronary Intervention// Diabetes Care. 2005. — V. 28. — P.873−77.
- Reiley M, Rader D. The Metabolic Syndrome: more the sum of its parts?// Circulation.-2003.-V.108.-P.1546−1551.
- Ridker P, Rifai N, Pfeffer M, et al. Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction// Circulation. 2000. — V. 101. — P.2149−2153.
- Riouful G., Finet G., Ginon I., Andre-Fouet X., et al. Multiple atherosclerotic plaque rapture in acute coronary syndrome: a three vessel intravascular ultrasound study//Circulation. 2002. — V. 106. — P.804−808.
- Ross R. Atherosclerosis: an inflammatory disease//N Eng J Med. 1999. -V. 340.-P.115−126.
- Saely C., Aczel S., Marte T., et al. The Metabolic Syndrome, Insulin Resistance, and Cardiovascular Risk in Diabetic and Nondiabetic Patients//J Clin Endocrinol Metab. 2005. — V.90. — P.5698−5703.
- Sanchis J., Body V., Nunes J., et al. Prognostic usefulness of white-blood cell count on admission and one-year outcome in patients with non-ST-elevation acute chest pain//Am J Cardiol. 2006. — V.98. — 885−9.
- Schwartz G., et al. Relation of characteristics of Metabolic Syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome//Diabetes Care. 2005. — V.28. — P.2508−2513.
- Selcuk H., Temizhan A., Selcuk M.T. Impact of metabolic syndrome on future cardiovascular events in patients with first acute myocardial infarction//Coronary Artery Disease. 2009. — V. 20. — P.370−375.
- Shindler TH, Nitzsche EU, Munzel T, et al. Coronary vasoregulation in patients with various risk factors in response to cold pressor testing//J Am Coll Cardiol. 2003. — V.42. — P.814−822.
- Shishehbor M, Brennan, Avules R, et al. Statins promote potent systemic antioxidant effects through specific inflammatory pathways//Circulation. 2003. -V.108. -426−431.
- Sobel B, Schneider D. Platelet function, coagulopathy, and impaired fibrinolisis in diabetes//Cardiol Clin. 2004. — V.22. — P.511−526.
- Sturm A. Cardiovascular genetics: are we there yet?//Journal of Medical Genetics. 2004. — V. 41. — P.321−323.
- Sundstrom J., Riserus U., Byberg L., Zethelius B., Lithell H., Lind L. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study//BMJ. -2006. — V.332. P.878−882.
- Suwaidi JA, Wright RS, Grill JP, et al. Obesity is associated with premature occurrence of acute myocardial infarction//Clin Cardiol. 2001. — V.24. — P.542−7.
- Suzuki T., Hirato K, Elkin M.S.V., et al. Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular events: The Northern Manhattan Study (NOMAS)//Am Heart J. 2008. — V.156,№ 2. — P.405−410.
- Takeno M., Yasuda S., Otsuka Y., Morii I., et al. Impact of metabolic syndrome on the long-term survival of patients with acute myocardial infarction: potential association with C-reactive protein//Circ J. 2008. — V.72. — P.415−19.
- Tall A. C-reactive protein reassessed//N Eng J Med. 2004. — V.350. — 14 501 452.
- Taniwaki H., Ishimura E., Matsumoto N., Emoto M., Inaba M., Nishizawa Y. Relations Between ACE Gene and eNOS Gene Polymorphisms and Resistive Index in Type 2 Diabetic Patients With Nephropathy//Diabetes Care. 2001. -V.24, № 9. — P. 1653−1660.
- Tenenbaum A., Adler Y., Boyko V., Tenenbaum H., et al. Insulin resistance is associated with increased risk of major cardiovascular events in patients with preexisting coronary artery disease//Am Heart J. 2007. — V.153, № 4. — P.559−65.
- Tenebaum A, Motro M, et al. Bezafibrate for the Secondary Prevention of Myocardial Infarction in Patients with Metabolic Syndrome//Arch Intern Med. -2005. V. 165. — P. 1154−1160.
- Tenerz A., Norhammar A., Silveira A., et al. Diabetes, Insulin Resistance, and the Metabolic Syndrome in Patients With Acute Myocardial Infarction Without Previously Known Diabetes//Diabetes Care. 2003. — V.26. — P.2770−76.
- The IDF consensus worldwide definition of Metabolic Syndrome. Brussels, Belgium: International Diabetes Federation, 2005. — 24 p.
- Trayhurn P, Beattie J. Physiological role of adipose tissue: White adipose tissue as an endocrine and secretory organ//Proc Nutr Soc. 2001. — V.60. -P.329−339.
- Uretsky S., Franz H.M., et al. Obesity Paradox in Patients with Hypertension and Coronary Artery Disease//The American Journal of Medicine. 2007. -V.120. — P.863−870.
- Wang X.L., Wang J. Endothelial nitric oxide synthase gene sequence variations and vascular disease//Molecular Genetics and Metabolism. 2000. -V.70. — P.241−251.
- Watanabe H., Tanabe N., Darbar D., et al. Metabolic Syndrome and Risk of Development of Atrial Fibrillation: The Niigata Preventive Medicine Study// Circulation. 2008. — V. l 17. — P.1255−1060.
- World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part I: Diagnosis and classification of diabetes mellitus. Geneva: WHO, 1999.
- Yang Z., Xiu-Fen Ming. Recent Advances in Understanding Endothelial Dysfunction in Atherosclerosis//Clin Med Res. 2006. — V.4, № 1. — P.53−65.
- Yeh E, Willerson J. Coming of age of C-ractive proteine: using inflammation markers in cardiology//Circulation. 2003. — V.107. — P.370−371.
- Yilmas B., Umit G., Yesim G., Hakan A., Burcu D., et al. Metabolic syndrome is associated with extension of coronary artery disease in patients with non-ST segment elevation acute coronary syndromes//Coronary Artery Disease. -V.16, №.5. P.287−292.
- Zeller M., Steg P., Ravisy J., et al. Prevalence and Impact of Metabolic Syndrome on Hospital Outcomes in Acute Myocardial Infarction//Archives of Internal Medicine. 2005 -V.165, № 10. — P. 1192−1198.
- Ziegler D. Diabetic Cardiovascular Autonomic Neuropathy: Prognosis, Diagnosis and Treatment. Diabetes/Metabolizm Reviews 1994- 10:4:164−171.